Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-07-19
2011-07-19
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024300, C536S024330, C536S024500
Reexamination Certificate
active
07981869
ABSTRACT:
The present invention is based on the in vivo demonstration that RSV can be inhibited through intranasal administration of iRNA agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based on these findings, the present invention provides general and specific compositions and methods that are useful in reducing RSV mRNA levels, RSV protein levels and viral titers in a subject, e.g., a mammal, such as a human. These findings can be applied to other respiratory viruses.
REFERENCES:
patent: 4501729 (1985-02-01), Boucher et al.
patent: 5693532 (1997-12-01), McSwiggen et al.
patent: 6107094 (2000-08-01), Crooke
patent: 6214805 (2001-04-01), Torrence et al.
patent: 6506559 (2003-01-01), Driver et al.
patent: 6881835 (2005-04-01), Bai et al.
patent: 7173015 (2007-02-01), Schreiber et al.
patent: 7507809 (2009-03-01), Meyers
patent: 7517865 (2009-04-01), Meyers
patent: 2002/0119936 (2002-08-01), Nyce
patent: 2003/0143732 (2003-07-01), Fosnaugh et al.
patent: 2003/0148928 (2003-08-01), Beigelman et al.
patent: 2003/0203356 (2003-10-01), Silverman et al.
patent: 2004/0204420 (2004-10-01), Rana
patent: 2004/0242518 (2004-12-01), Chen et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2005/0008617 (2005-01-01), Chen et al.
patent: 2005/0107325 (2005-05-01), Manoharan et al.
patent: 2005/0267300 (2005-12-01), Manoharan et al.
patent: 2006/0084620 (2006-04-01), McCray et al.
patent: 2006/0089323 (2006-04-01), Barik
patent: 2006/0287267 (2006-12-01), Vaish et al.
patent: 2045183 (1995-10-01), None
patent: WO 98/12312 (1998-03-01), None
patent: WO 2004/064737 (2004-08-01), None
patent: WO 2004/080406 (2004-09-01), None
patent: WO 2004/090108 (2004-10-01), None
patent: WO 2004/094345 (2004-11-01), None
patent: WO 2004/094595 (2004-11-01), None
patent: WO 2005/076999 (2005-08-01), None
patent: WO 2005/097817 (2005-10-01), None
patent: WO 2006/062596 (2006-06-01), None
patent: WO 2006/121464 (2006-11-01), None
Second Office Action, The State Intellectual Property Office of the People's Republic of China, Patent Application No. 200680004735.5, Dec. 25, 2009, 6 Pages.
Third Office Action, The State Intellectual Property Office of the People's Republic of China, Patent Application No. 200680004735.5, Mar. 29, 2010 6 Pages.
Search Report and Written Opinion, Intellectual Property Office of Singapore, Patent application No. 200705015-6, Oct. 20, 2009, 9 Pages.
Agrawal, S., et al., “Antisense therapeutics: is it as simple as complementary base recognition?” Molecular Medicine Today, Feb. 2000, p. 72-81, vol. 6.
Barik, S., “Control of nonsegmented negative-strand RNA virus replication by siRNA” Virus Research, 2004, pp. 27-35, vol. 102.
Bernhard, W., et al., “Phosphatidylcholine Molecular Species in Lung Surfactant,” American Journal of Respiratory Cell and Molecular Biology, 2001, p. 725-731, vol. 25.
Bitko, V., et al., “Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses” BMC Microbiology, Dec. 20, 2001, 11 Pages, vol. 1, No. 34.
Bridge, A.J., et al., “Induction of an interferon response by RNAi vectors in mammalian cells,” Nature Genetics, Jul. 2003, p. 263-264, vol. 34.
Burke, E., et al., “Profilin Is Required for Optimal Actin-Dependent Transcription of Respiratory Syncytial Virus Genome RNA” Journal of Virology, Jan. 2000, pp. 669-675, vol. 74, No. 2.
Burke, E., et al., “Role of Cellular Actin ill the Gene Expression and Morphogenesis of Human Respiratory Syncytial Virus” Virology, 1998, vol. 252, pp. 137-148.
Caplen, N., “RNAi as a gene therapy approach,” Expert Opinion Biol. Ther., 2003, p. 575-586, vol. 3, Issue 4.
Check, E., “RNA to the rescue?” Nature, Sep. 4, 2003, p. 10-12, vol. 425.
Coiras, M.T., et al., “Simultaneous Detection of Fourteen Respiratory Viruses in Clinical Specimens by Two Multiplex Reverse Transcription Nested—PCR Assays,” Journal of Medical Virology, 2004, p. 484-495, vol. 72.
Crooke, S., “Chapter 1—Basic Principles of Antisense Therapeutics,” Antisense Research and Application, 1998, pp. 1-50, New York.
Das, “Human Immunodeficiency Virus Type 1 Escapes from RNA Interference-Mediated Inhibition,” Journal of Virology, Mar. 2004, p. 2601-2605, vol. 78, No. 5.
Durbin, A.P., et al., “African green monkeys provide a useful nonhuman primate model for the study of human parainfluenza virus types -1, -2, and -3 infection,” Vaccine, 2000, p. 2462-2469, vol. 18.
Durbin, J.E., et al., “The Role of IFN in Respiratory Syncytial Virus Pathogensis,” Journal of Immunology, 2002, p. 2944-2952.
Easton, A., et al., “Animal Pneumoviruses: Molecular Genetics and Pathogenesis” Clinical Microbiology Reviews, Apr. 2004, pp. 390-412, vol. 17, No. 2.
Elbashir, S.M., et al., “Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells,” Nature, May 24, 2001, p. 494-498, vol. 411.
Elbashir, S.M., et al., “RNA interference is mediated by 21- and 22-nucleotide RNAs” Genes Dev., 2001, vol. 15, pp. 188-200.
Falsey, A., et al., “Respiratory Syncytial Virus Infection in Adults” Clin. Microbiol. Rev., Jul. 2000, vol. 13, pp. 371-384.
Fire, A., et al., “Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans” Nature 1998, vol. 391, pp. 806-811.
Freymouth, et al., “Detection of respiratory syncytial virus, parainfluenzavirus 3, adenovirus and rhinovirus sequences in respiratory tract of infants by polymerase chain reaction and hybridization,” Clinical and Diagnostic Virology, 1997, p. 31-40, vol. 8.
Ge, et al., “Inhibition of influenza virus production in virus-infected mice by RNA interference,” Proceedings of the national Academy of Sciences of the United States of America, Jun. 8, 2004, p. 8676-8681, vol. 101, No. 23.
GenBank Accession No. M22644 (Aug. 3, 1993), NCBI Sequence Viewer v2.0, [online] [Retrieved on May 8, 2008] Retrieved from the internet URL:http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=333949.
GenBank Accession No. NC—001796 (Dec. 29, 2003), NCBI Sequence Viewer v2.0, [online] [Retrieved on May 8, 2008] Retrieved from the internet URL:http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=10937870.
GenBank Accession No. X65324 (Jan. 9, 2003), NCBI Sequence Viewer v2.0, [online] [Retrieved on May 8, 2008] Retrieved from the internet URL:http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=27650340.
GenBank Accession No. Z11575 (Nov. 23, 1999), NCBI Sequence Viewer v2.0, [online] [Retrieved on May 8, 2008] Retrieved from the internet URL:http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=61410.
Graham, B.S. et al., “Primary Respiratory Syncytial Virus infection in Mice,” Journal of Medical Virology, 1988, p. 153-162, vol. 26.
Gupta, S., et al., “Involvement of Actin Microfilaments in the Replication of Human Parainfluenza Virus Type 3” Journal of Virology, Apr. 1998, vol. 72, No. 4, pp. 2655-2662.
Haeberle, H.A., et al., “Inducible Expression of Inflammatory Chemokines in Respiratory Syncytial Virus-Infected Mice: Role of MIP-1α in Lung Pathology,” Journal of Virology, Jan. 2001, p. 878-890, vol. 75, No. 2.
Hannon, G., et al., “Unlocking the potential of the human genome with RNA interference,” Nature, Sep. 16, 2004, p. 371-378, vol. 431.
Haynes, L., et al., “Enhanced Disease and Pulmonary Eosinophilia Associated with Formalin-Inactivated Respiratory Syncytial Virus Vaccination Are Linked to F Glycoprotein CX3C-CX3CRI Interaction and Expression of Substance P, ” Journal of Virology, Sep. 2003, vol. 77, No. 18, pp. 9831-
Alnylam Pharmaceuticals, Inc.
Fenwick & West LLP
Gibbs Terra Cotta
McGarry Sean
LandOfFree
RNAi modulation of RSV and therapeutic uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with RNAi modulation of RSV and therapeutic uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RNAi modulation of RSV and therapeutic uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2645780